[
  {
    "ts": null,
    "headline": "Is CVS Health Corporation (CVS) the Best Pharma Dividend Stock to Buy In 2024?",
    "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but […]",
    "url": "https://finnhub.io/api/news?id=eec7a19601a9934f1dee8e61af0bc9fe0398b2f989c0df919d539eeceb98f0df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735594422,
      "headline": "Is CVS Health Corporation (CVS) the Best Pharma Dividend Stock to Buy In 2024?",
      "id": 132208480,
      "image": "https://s.yimg.com/ny/api/res/1.2/d6hiuhfSWIMOKtD72OdXqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4e33e0d1a07889115aefcb74e0ea299f",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but […]",
      "url": "https://finnhub.io/api/news?id=eec7a19601a9934f1dee8e61af0bc9fe0398b2f989c0df919d539eeceb98f0df"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Drops on Reform Fears -- Health Care Roundup",
    "summary": "Health Care Drops on Reform Fears -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=5ad282f22c2f50adef577a191806c80dac26b67b50b4126c768b7191ec00d866",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735576800,
      "headline": "Health Care Drops on Reform Fears -- Health Care Roundup",
      "id": 132329050,
      "image": "",
      "related": "CVS",
      "source": "MarketWatch",
      "summary": "Health Care Drops on Reform Fears -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=5ad282f22c2f50adef577a191806c80dac26b67b50b4126c768b7191ec00d866"
    }
  },
  {
    "ts": null,
    "headline": "5 Value Stocks That Could Get a Bump From Activist Investors",
    "summary": "5 Value Stocks That Could Get a Bump From Activist Investors",
    "url": "https://finnhub.io/api/news?id=4bb1f229b739d94e6992d02a009d24da1243d8ac6c2492141bab8b33bc9a2c22",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735572720,
      "headline": "5 Value Stocks That Could Get a Bump From Activist Investors",
      "id": 132322916,
      "image": "",
      "related": "CVS",
      "source": "MarketWatch",
      "summary": "5 Value Stocks That Could Get a Bump From Activist Investors",
      "url": "https://finnhub.io/api/news?id=4bb1f229b739d94e6992d02a009d24da1243d8ac6c2492141bab8b33bc9a2c22"
    }
  },
  {
    "ts": null,
    "headline": "Drug Middlemen Spared by Trump and Musk, for Now",
    "summary": "Tucked into the bipartisan budget deal that President-elect  Donald Trump’s  allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system.  Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.",
    "url": "https://finnhub.io/api/news?id=f46b69a891dc4086d7e9df1c9af657770eebe7d7eae3125bd692a48e06dede5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735554600,
      "headline": "Drug Middlemen Spared by Trump and Musk, for Now",
      "id": 132201376,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Tucked into the bipartisan budget deal that President-elect  Donald Trump’s  allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system.  Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.",
      "url": "https://finnhub.io/api/news?id=f46b69a891dc4086d7e9df1c9af657770eebe7d7eae3125bd692a48e06dede5d"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth’s Army of Doctors Helped It Collect Billions More From Medicare",
    "summary": "The biggest Medicare Advantage insurer presented physicians with checklists of potential diagnose.; “I didn’t think I was obese,” one suspicious patient told his doctor.",
    "url": "https://finnhub.io/api/news?id=82d52f1b2080fe040107aa58145c56a39d49aa261e2f5d5326a42c09ff3f1e02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735524000,
      "headline": "UnitedHealth’s Army of Doctors Helped It Collect Billions More From Medicare",
      "id": 132200278,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The biggest Medicare Advantage insurer presented physicians with checklists of potential diagnose.; “I didn’t think I was obese,” one suspicious patient told his doctor.",
      "url": "https://finnhub.io/api/news?id=82d52f1b2080fe040107aa58145c56a39d49aa261e2f5d5326a42c09ff3f1e02"
    }
  }
]